Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of coronary stent restenosis in adults with type 2 diabetes after PCI
ACTRN12625000924459Phase 4Not yet recruiting
- Sponsor
- Northern Health
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis comparing Empagliflozin arm with Standard of care non-SGLT2 inhibitor diabetes therapy arm (2 arms). Primary endpoint: Late lumen loss. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12625000924459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000924459.